BioMarin Pharmaceutical Q1 Earnings Call Highlights

Key Points

• BioMarin closed the acquisition of Amicus, adding therapies Galafold and Pombiliti/Opfolda, which management says expands portfolio diversification and accelerates 2026 year‑over‑year revenue growth to about 20% at the midpoint.
• Updated 2026 guidance (including Amicus) raises enzyme therapies revenue to $2.725–$2.775 billion and total revenue to $3.825–$3.925 billion (≈20% midpoint); the deal is expected to be slightly dilutive in 2026 but accretive within 12 months and substantially accretive beginning in 2027, with more than 55% of revenue and roughly two‑thirds of EPS weighted to H2.
• Operational and pipeline highlights: Q1 revenue was $766 million driven by enzyme therapies and Voxzogo, BioMarin submitted an sNDA for Voxzogo full approval, expects two pivotal Q2 readouts (Voxzogo in hypochondroplasia and BMN‑401), and reported early momentum from the Palynziq adolescent launch despite new U.S. competition for Voxzogo.

BioMarin Pharmaceutical NASDAQ: BMRN executives emphasized an expanded commercial portfolio and an updated 2026 growth outlook during the company’s first-quarter 2026 earnings call, highlighted by the recent close of its acquisition of Amicus. Management said the transaction adds two therapies—Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease—and accelerates BioMarin’s anticipated year-over-year 2026 revenue growth to about 20% at the midpoint of updated guidance.

Amicus acquisition closes; integration plan takes shape

President and CEO Alexander Hardy said the Amicus deal closed last week and described it as “a new and exciting chapter” that increases portfolio diversification. He said BioMarin has been preparing for “rapid integration beginning on day one,” with a targeted plan aimed at leveraging BioMarin’s scale to “drive diagnosis and treatment rates for patients with Fabry disease and late-onset Pompe disease.”

Hardy said the company expects to share an integration “roadmap” next quarter, including more detail on growth acceleration from the addition of Galafold and Pombiliti and Opfolda, as well as the addition of DMX-200 for FSGS to the late-stage pipeline (which he noted is in Phase 3).

In the Q&A, management reiterated that BioMarin intends to provide additional detail next quarter on long-term commercial potential, including peak revenue views, along with financial elements such as cost synergies, long-term profitability, and accretion. Executives also referenced previously discussed peak revenue potential of roughly $1 billion each for Galafold and for Pombiliti and Opfolda, while noting BioMarin believes the products could have “potential to be higher” as plans are developed.

First-quarter results: revenue growth supported by demand, offset by timing

Chief Financial Officer Brian Mueller said total revenues in the first quarter were $766 million, up year-over-year, driven by increased patient demand across enzyme therapies and Voxzogo. He said that organic growth was “partly offset by order timing dynamics” and lower revenue from Roctavian, Kuvan, and royalties.

Mueller reported enzyme therapies revenue increased 6% year-over-year, led by Vimizim, Naglazyme, and Brineura. He said Palynziq revenue in the quarter was affected by U.S. order timing that resulted in “elevated stocking levels” in the fourth quarter of 2025, a dynamic he expects to normalize. Mueller said BioMarin anticipates year-over-year revenue growth for Palynziq for full-year 2026 as new patient starts in the under-18 population increase and patients titrate to maintenance dose.

Voxzogo revenue was supported by new patient starts across regions and was described as in line with prior expectations. However, Mueller said the company expects Voxzogo revenue to be higher in the second half of 2026 than the first half, consistent with anticipated order timing.

Updated 2026 guidance incorporates Amicus; profitability weighted to second half

Mueller outlined updated full-year 2026 guidance, now including the Amicus outlook starting last week. BioMarin raised enzyme therapies revenue guidance to $2.725 billion to $2.775 billion, which Mueller said is inclusive of “meaningful contributions” from Galafold and Pombiliti and Opfolda and represents about 30% growth at the midpoint. Total revenue guidance was increased to $3.825 billion to $3.925 billion, with the midpoint representing about 20% year-over-year growth.

For Voxzogo, BioMarin maintained its revenue guidance of $975 million to $1.025 billion, which Mueller said reflects high single-digit growth at the midpoint.

Non-GAAP diluted earnings per share guidance was updated to $4.85 to $5.05. Mueller reiterated the company’s view that the Amicus acquisition will be “slightly diluted” for full-year 2026, but “accretive to non-GAAP diluted earnings per share in the first 12 months after close” and “substantially accretive beginning in 2027.”

Mueller also provided timing expectations for 2026 results, stating BioMarin expects more than 55% of total 2026 revenues to be recognized in the second half of the year, with roughly two-thirds of earnings per share expected in the second half. He said the company expects second-quarter non-GAAP EPS to be only modestly higher than the first quarter, partly due to pre-close Amicus costs incurred in April and a greater portion of Amicus dilution being weighted to Q2.

Mueller noted BioMarin is monitoring geopolitical uncertainties in the Middle East and said guidance includes an allowance for a “modest amount of disruption” in the region in 2026.

Commercial update: Palynziq adolescent launch, Voxzogo momentum amid competitor entry

Chief Commercial Officer Cristin Hubbard said BioMarin was encouraged by execution across the portfolio, citing strong demand across enzyme therapies and Voxzogo. On Palynziq, Hubbard pointed to the February FDA approval expanding the U.S. label to patients ages 12 and older and said BioMarin has “successfully launched in this age group” with “encouraging early momentum.” She said the company has observed “meaningful enrollments and new patient starts” among those under 18, driven by both experienced prescribers and clinicians newer to the therapy. Hubbard noted the titration process can take many months, and she said BioMarin expects the impact of early prescribing to show over coming quarters. She also said European approval is expected later this year.

For Voxzogo, Hubbard said first-quarter results reflected expected order timing dynamics following a strong fourth quarter, particularly in international markets. She said global patient additions remained strong, with the number of children treated increasing by more than 20% year-over-year. Hubbard acknowledged a competitor recently entered the U.S. market, but said BioMarin remains focused on execution and continues to see momentum. She highlighted an emphasis on children under age 2, stating that in the U.S., over half of new patient starts in Q1 were in the under-2 cohort and that the average age of initiating treatment in that segment declined, narrowing the time between diagnosis and treatment starts.

In Q&A, Hubbard said BioMarin’s Q1 Voxzogo enrollments exceeded the average of the second half of last year and that the trend continued into April. Mueller later addressed the gap between patient growth and revenue growth, saying the “disconnect” was “entirely order timing,” including large international orders in Q4 that did not recur in Q1 and “a modest amount of U.S. stocking impact” affecting both Palynziq and Voxzogo.

Pipeline and regulatory: Voxzogo full approval submission; pivotal readouts expected in Q2

Hardy said BioMarin submitted an sNDA for Voxzogo for full approval and expects to learn the review timing in coming months. Chief R&D Officer Greg Freiberg described a “comprehensive Voxzogo evidence package” and said BioMarin recently shared long-term extension data showing sustained improvements over six to eight years of follow-up, along with quality-of-life measures and a safety database exceeding 10,000 patient-years of exposure. Freiberg said these data supported the FDA submission made in April.

Freiberg said BioMarin expects two pivotal top-line readouts in the second quarter: Voxzogo in hypochondroplasia and BMN 401 in ENPP1 deficiency. He described BMN 401’s Phase 3 ENERGY-3 study as including two co-primary endpoints: changes in plasma measures of inorganic pyrophosphate through week 52 and changes in RGIC after 52 weeks assessing skeletal health.

Freiberg also said enrollment is underway in BioMarin’s global registrational Phase 2/3 study for BMN 333, a long-acting CNP therapy in achondroplasia. He said the company expects to report annualized growth velocity at the six-month time point in 2027 as part of selecting a dose to advance. In separate remarks, Freiberg discussed initial data for BMN 351 in Duchenne muscular dystrophy presented in March, including dose-dependent dystrophin increases at week 25 in two cohorts, decreases in creatine kinase, and prevention of functional decline compared to historically matched controls, with enrollment ongoing in a higher-dose cohort and an additional update expected by year-end.

On legal matters, Hardy said BioMarin recently completed an ITC evidentiary hearing and expects a decision on whether Ascendis’s product infringes BioMarin’s patent “on or about August 21st,” with a potential final decision “on or about December 21st” if reviewed by the full commission. Hardy also said BioMarin would expect to enforce its patent in federal district court following completion of the ITC process, where monetary damages are available.

About BioMarin Pharmaceutical NASDAQ: BMRN

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.